Results, however, indicated that MSC-NP improved walking ability for people with more advanced disease — those who need an aid to walk short distances. Patients treated with MSC-NP also often reported fewer bladder problems following treatment.
“The findings of this study suggest that stem cells could have major implications for treating MS and reversing patient disability even after significant progression,” Violaine Harris, PhD, a principal trial investigator at the Tisch MS Research Center of New York, said in a center press release.
They “are unprecedented in the realm of researching stem cells as a treatment pathway for progressive MS patients,” added Saud Sadiq, the Tisch Center’s director and chief research scientist. For a first time, “we have seen a regenerative treatment improve patient outcomes in multiple areas, providing strong evidence of the potential efficacy of stem cells in patients with significant and varying disabilities.